Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.10.0.1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
 3 Months Ended 12 Months Ended
Aug. 31, 2018
May 31, 2016
May 31, 2018
Commitments and Contingencies [Line Items]      
Asset Purchase Agreement Aggregate Consideration Paying Period 10 years    
Payment to acquire other assets   $ 1,500,000  
Prepaid execution fees for process validation and manufacturing activities $ 2,451,983   $ 1,862,009
Minimum      
Commitments and Contingencies [Line Items]      
Royalty on every net sales 0.75%    
Maximum      
Commitments and Contingencies [Line Items]      
Royalty on every net sales 2.00%    
Development Milestone Payments      
Commitments and Contingencies [Line Items]      
Asset Purchase Agreement Aggregate Consideration Paying Period 10 years    
Minimum annual license maintenance fees $ 150,000    
Project Work Order | Termination of Any One Clinical Trial | Minimum      
Commitments and Contingencies [Line Items]      
Financial penalties 100,000    
Project Work Order | Termination of Any One Clinical Trial | Maximum      
Commitments and Contingencies [Line Items]      
Financial penalties 1,400,000    
Project Work Order | Termination of All Clinical Trials | Minimum      
Commitments and Contingencies [Line Items]      
Financial penalties 500,000    
Project Work Order | Termination of All Clinical Trials | Maximum      
Commitments and Contingencies [Line Items]      
Financial penalties 2,300,000    
Contract Manufacturing Companies      
Commitments and Contingencies [Line Items]      
Execution fees for process validation and manufacturing activities 2,100,000    
Prepaid execution fees for process validation and manufacturing activities 700,000    
Contract Manufacturing Companies | Termination of Any One Clinical Trial | Maximum      
Commitments and Contingencies [Line Items]      
Financial penalties 1,700,000    
Biologic License Application with the FDA or Non-U.S. Equivalent Regulatory Body | Milestone Payments      
Commitments and Contingencies [Line Items]      
Potential future milestone and royalties payments 500,000    
First U.S. New Drug Application Approval by the FDA or Other Non-U.S. Approval | Milestone Payments      
Commitments and Contingencies [Line Items]      
Potential future milestone and royalties payments $ 5,000,000    
Royalty on every net sales 5.00%    
FDA Approval or Approval by Another Non-U.S. Equivalent Regulatory Body | Development Milestone Payments      
Commitments and Contingencies [Line Items]      
Potential future milestone and royalties payments $ 500,000    
Royalty on every net sales 3.50%